Last updated on December 2019

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)


Brief description of study

To evaluate efficacy, safety and pharmacokinetic profile of asciminib 40mg+imatinib or asciminib 60mg+imatinib versus continued imatinib and versus nilotinib in pre-treated patients with Chronic Myeloid Leukemia in chronic phase (CML-CP)

Clinical Study Identifier: NCT03578367

Find a site near you

Start Over

Novartis Investigative Site

Melbourne, Australia
2.08miles
  Connect »